Name | Number of supported studies | Average coverage | |
---|---|---|---|
ciliated cell | 17 studies | 50% ± 17% | |
enterocyte | 6 studies | 53% ± 29% | |
goblet cell | 3 studies | 27% ± 3% | |
intestinal crypt stem cell | 3 studies | 35% ± 20% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
intestine | 3 studies | 33% ± 18% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
adrenal gland | 97% | 331.21 | 251 / 258 | 70% | 42.46 | 162 / 230 |
brain | 98% | 529.56 | 2587 / 2642 | 20% | 2.77 | 139 / 705 |
lung | 46% | 145.74 | 263 / 578 | 52% | 11.85 | 596 / 1155 |
bladder | 24% | 22.67 | 5 / 21 | 73% | 35.84 | 366 / 504 |
intestine | 22% | 5472.84 | 208 / 966 | 71% | 24.16 | 374 / 527 |
kidney | 1% | 0.76 | 1 / 89 | 67% | 40.59 | 608 / 901 |
stomach | 3% | 2.09 | 9 / 359 | 62% | 19.58 | 178 / 286 |
ovary | 2% | 2.21 | 4 / 180 | 50% | 15.07 | 214 / 430 |
esophagus | 9% | 9.08 | 126 / 1445 | 42% | 6.95 | 77 / 183 |
tonsil | 0% | 0 | 0 / 0 | 49% | 16.82 | 22 / 45 |
pancreas | 0% | 0 | 0 / 328 | 42% | 8.79 | 75 / 178 |
lymph node | 0% | 0 | 0 / 0 | 41% | 7.21 | 12 / 29 |
uterus | 6% | 42.43 | 11 / 170 | 32% | 8.46 | 148 / 459 |
heart | 19% | 17.21 | 163 / 861 | 0% | 0 | 0 / 0 |
breast | 1% | 3.02 | 3 / 459 | 14% | 2.64 | 160 / 1118 |
peripheral blood | 12% | 13.53 | 116 / 929 | 0% | 0 | 0 / 0 |
skin | 2% | 1.32 | 30 / 1809 | 6% | 1.21 | 27 / 472 |
liver | 0% | 0 | 0 / 226 | 6% | 1.28 | 26 / 406 |
thymus | 0% | 0.21 | 2 / 653 | 3% | 0.80 | 20 / 605 |
prostate | 0% | 0 | 0 / 245 | 1% | 0.12 | 4 / 502 |
adipose | 0% | 0.21 | 4 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 0% | 0.21 | 3 / 1335 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
muscle | 0% | 0 | 0 / 803 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spleen | 0% | 0 | 0 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0015908 | Biological process | fatty acid transport |
GO_0008285 | Biological process | negative regulation of cell population proliferation |
GO_0006629 | Biological process | lipid metabolic process |
GO_0005829 | Cellular component | cytosol |
GO_0016020 | Cellular component | membrane |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0005504 | Molecular function | fatty acid binding |
GO_0008289 | Molecular function | lipid binding |
Gene name | FABP6 |
Protein name | Gastrotropin (GT) (Fatty acid-binding protein 6) (Ileal lipid-binding protein) (ILBP) (Intestinal 15 kDa protein) (I-15P) (Intestinal bile acid-binding protein) (I-BABP) Fatty acid binding protein 6 |
Synonyms | ILLBP ILBP |
Description | FUNCTION: Binds to bile acids and is involved in enterohepatic bile acid metabolism. Required for efficient apical to basolateral transport of conjugated bile acids in ileal enterocytes (By similarity). In vitro binds to bile acids in the order: deoxycholic acid > cholic acid > chenodeoxycholic acid and respective BA conjugation modifies affinities in the order taurine-conjugated > glycine-conjugated > unconjugated bile acids. Stimulates gastric acid and pepsinogen secretion (By similarity). .; FUNCTION: [Isoform 2]: Essential for the survival of colon cancer cells to bile acid-induced apoptosis. . |
Accessions | ENST00000523955.5 ENST00000393980.8 [P51161-2] ENST00000402432.4 [P51161-1] P51161 H0YB64 |